Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00099775|
Recruitment Status : Completed
First Posted : December 20, 2004
Last Update Posted : March 4, 2008
This study will examine whether the anti-fungal drug caspofungin can prevent Candida infections in adult patients in intensive care units (ICUs). Caspofungin is approved to treat certain fungal infections, including fungal blood stream infections due to Candida. Because ICU patients are at high risk for Candida, it would be beneficial to have a preventive drug, thereby reducing complications due to infection.
Patients 18 years of age or older who are not pregnant may be enrolled in this study on day 3 or 4 of their ICU admission if they have an expected stay of at least 2 additional days in the ICU.
Participants are randomly assigned to treatment with either caspofungin or placebo (an inactive substance). Before treatment, patients have a medical history and physical examination. Blood and urine tests are done for routine tests and to look for fungal infection. Additional samples that may be collected to test for fungal infection include a rectal swab or stool sample; a wound culture if the patient has a wound, or a sputum culture in patients who have a tube in their throat to help with breathing or are producing sputum.
Patients take caspofungin or placebo once a day for no more than 28 days. In addition, they undergo the following procedures:
- Review of treatment side effects and medicines taken, daily during treatment, 1 week after treatment, and 2 weeks after treatment
- Physical examination once a week, on the last day of treatment, and 1 week after treatment
- Urine test once a week, on the last day of treatment, and 1 week after treatment to look for possible fungal infection
- Blood tests twice a week, on the last day of treatment, 1 week after treatment, and 2 weeks after treatment for laboratory safety tests and to look for fungal infection
- Collection of additional samples (rectal swab or stool sample, wound culture, or sputum sample) once a week, on the last day of treatment, and 1 week after treatment to look for possible fungal infection
|Condition or disease||Intervention/treatment||Phase|
|Candidiasis||Drug: Caspofungin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||1200 participants|
|Official Title:||A Randomized Double-Masked Trial of Caspofungin Versus Placebo as Prophylaxis of Invasive Candidiasis in High-Risk Adults in the Critical Care Setting|
|Study Start Date :||December 2004|
|Study Completion Date :||September 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00099775
|United States, Maryland|
|National Cancer Institute (NCI)|
|Bethesda, Maryland, United States, 20892|